{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:19:46Z","timestamp":1794226786539,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00342763"],"award-info":[{"award-number":["RS-2024-00342763"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2023R1A2C1003830"],"award-info":[{"award-number":["2023R1A2C1003830"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korea Health Technology R&D Project through the Korea Health Industry Development Institute","award":["RS-2024-00439816"],"award-info":[{"award-number":["RS-2024-00439816"]}],"id":[{"id":"https:\/\/ror.org\/00fdzyk40","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Korea Health Technology R&D Project through the Korea Health Industry Development Institute","award":["RS-2025-02263117"],"award-info":[{"award-number":["RS-2025-02263117"]}],"id":[{"id":"https:\/\/ror.org\/00fdzyk40","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"DOI":"10.1186\/s10020-026-01535-z","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:05:25Z","timestamp":1782450325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncolytic adenovirus co-expressing IL-12 and shVEGF potentiates immune checkpoint blockade for treatment of renal cell carcinoma: in vitro, organ-on-a-chip, and in vivo evaluation"],"prefix":"10.1186","volume":"32","author":[{"given":"Joongwon","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejung","family":"Maeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Ho","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Rum","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"51","key":"1535_CR1","doi-asserted-by":"publisher","first-page":"84965","DOI":"10.18632\/oncotarget.13087","volume":"7","author":"HM Ahn","year":"2016","unstructured":"Ahn HM, Hong J, Yun CO. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy. Oncotarget. 2016;7(51):84965\u201380. https:\/\/doi.org\/10.18632\/oncotarget.13087. PubMed PMID: 27821803; PubMed Central PMCID: PMCPMC5356712.","journal-title":"Oncotarget"},{"issue":"1","key":"1535_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s10020-025-01223-4","volume":"31","author":"HM Ahn","year":"2025","unstructured":"Ahn HM, Jung BK, Hong J, Hong D, Yoon AR, Yun CO. Enhanced potency of immune checkpoint inhibitors against poorly immunological solid tumors by immune stimulatory oncolytic adenoviruses-mediated remodeling of the tumor microenvironment. Mol Med. 2025;31(1):175. https:\/\/doi.org\/10.1186\/s10020-025-01223-4. PubMed PMID: 40335925; PubMed Central PMCID: PMCPMC12057182. Epub 20250507.","journal-title":"Mol Med"},{"key":"1535_CR3","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.3389\/fimmu.2018.03120","volume":"9","author":"A Amin","year":"2018","unstructured":"Amin A, Hammers H. The evolving landscape of immunotherapy-based combinations for frontline treatment of advanced renal cell carcinoma. Front Immunol. 2018;9:3120. https:\/\/doi.org\/10.3389\/fimmu.2018.03120.","journal-title":"Front Immunol"},{"issue":"1","key":"1535_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.eururo.2022.10.010","volume":"83","author":"J Bedke","year":"2022","unstructured":"Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Ljungberg B, et al. The 2022 updated European association of urology guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma. Eur Urol. 2022;83(1):10\u20134. https:\/\/doi.org\/10.1016\/j.eururo.2022.10.010.","journal-title":"Eur Urol"},{"key":"1535_CR5","doi-asserted-by":"publisher","first-page":"1610858","DOI":"10.3389\/fimmu.2025.1610858","volume":"16","author":"C Cheng","year":"2025","unstructured":"Cheng C, Wang Q, Zhang S. Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms. Front Immunol. 2025;16:1610858. https:\/\/doi.org\/10.3389\/fimmu.2025.1610858.","journal-title":"Front Immunol"},{"issue":"4","key":"1535_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s13206-023-00125-z","volume":"17","author":"SY Choi","year":"2023","unstructured":"Choi SY, Kim M, Kang SJ, Choi YW, Maeng S, Kim S-H, et al. Enhanced antitumor effect of the combination of Bacille Calmette-Gu\u00e9rin and an immune checkpoint inhibitor in bladder cancer-on-a-chip. BioChip J. 2023;17(4):496\u2013506. https:\/\/doi.org\/10.1007\/s13206-023-00125-z.","journal-title":"BioChip J"},{"key":"1535_CR7","doi-asserted-by":"publisher","unstructured":"Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;(1):CD001425. Epub 20050125. https:\/\/doi.org\/10.1002\/14651858.CD001425.pub2. PubMed PMID: 15674877.","DOI":"10.1002\/14651858.CD001425.pub2"},{"key":"1535_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_280817","volume":"40","author":"JP Dutcher","year":"2020","unstructured":"Dutcher JP, Flippot R, Fallah J, Escudier B. On the shoulders of giants: the evolution of renal cell carcinoma treatment-cytokines, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book. 2020;40:1\u201318. https:\/\/doi.org\/10.1200\/edbk_280817. PubMed PMID: 32243201.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"1535_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2019.10.025","volume":"77","author":"B Escudier","year":"2020","unstructured":"Escudier B, Motzer RJ, Tannir NM, Porta C, Tomita Y, Maurer MA, et al. Efficacy of Nivolumab plus Ipilimumab according to number of IMDC risk factors in CheckMate 214. Eur Urol. 2020;77(4):449\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2019.10.025.","journal-title":"Eur Urol"},{"issue":"5","key":"1535_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1535_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","volume":"5","author":"R Garcia-Carbonero","year":"2017","unstructured":"Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer. 2017;5(1):71. https:\/\/doi.org\/10.1186\/s40425-017-0277-7.","journal-title":"J Immunother Cancer"},{"key":"1535_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","volume":"16","author":"MK Gately","year":"1998","unstructured":"Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12\/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495\u2013521. https:\/\/doi.org\/10.1146\/annurev.immunol.16.1.495. PubMed PMID: 9597139.","journal-title":"Annu Rev Immunol"},{"key":"1535_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/978-1-0716-3291-8_19","volume":"2684","author":"P Grandi","year":"2023","unstructured":"Grandi P, Darilek A, Moscu A, Pradhan A, Li R. Intravesical infusion of oncolytic virus CG0070 in the treatment of bladder cancer. Methods Mol Biol. 2023;2684:303\u201317. https:\/\/doi.org\/10.1007\/978-1-0716-3291-8_19. PubMed PMID: 37410243.","journal-title":"Methods Mol Biol"},{"issue":"17","key":"1535_CR14","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/jco.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205\u201318. https:\/\/doi.org\/10.1200\/jco.2012.46.3653. PubMed PMID: 23669226; PubMed Central PMCID: PMCPMC3731977. Epub 20130513.","journal-title":"J Clin Oncol."},{"key":"1535_CR15","doi-asserted-by":"publisher","first-page":"639636","DOI":"10.3389\/fimmu.2021.639636","volume":"12","author":"Y Jian","year":"2021","unstructured":"Jian Y, Yang K, Sun X, Zhao J, Huang K, Aldanakh A, et al. Current advance of immune evasion mechanisms and emerging immunotherapies in renal cell carcinoma. Front Immunol. 2021;12:639636. https:\/\/doi.org\/10.3389\/fimmu.2021.639636.","journal-title":"Front Immunol"},{"issue":"9","key":"1535_CR16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475\u201385. https:\/\/doi.org\/10.1038\/s12276-020-00500-y.","journal-title":"Exp Mol Med"},{"key":"1535_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41434-025-00540-x","volume":"32","author":"L Liu","year":"2025","unstructured":"Liu L, Song L, Liu T, Hui K, Hu C, Yang J, et al. Recombinant oncolytic virus NDV-anti-VEGFR2 enhances radiotherapy sensitivity in NSCLC by targeting VEGF signaling and impairing DNA repair. Gene Ther. 2025;32:517. https:\/\/doi.org\/10.1038\/s41434-025-00540-x. PubMed PMID: 40382521. Epub 20250517.","journal-title":"Gene Ther"},{"issue":"3","key":"1535_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11255-010-9866-9","volume":"43","author":"W Liu","year":"2011","unstructured":"Liu W, Cao Y, Fernandez MI, Niu H, Xiu Y. Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo. Int Urol Nephrol. 2011;43(3):721\u20137. https:\/\/doi.org\/10.1007\/s11255-010-9866-9.","journal-title":"Int Urol Nephrol"},{"issue":"34","key":"1535_CR19","first-page":"65","volume":"14","author":"JE Logan","year":"2012","unstructured":"Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, et al. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol. 2012;14(34):65\u201378. PubMed PMID: 23526579; PubMed Central PMCID: PMCPMC3602729.","journal-title":"Rev Urol."},{"issue":"35","key":"1535_CR20","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1200\/JCO.2006.08.5415","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24(35):5601\u20138. https:\/\/doi.org\/10.1200\/JCO.2006.08.5415. PubMed PMID: 17158546.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1535_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324. https:\/\/doi.org\/10.1056\/NEJMoa065044. PubMed PMID: 17215529.","journal-title":"N Engl J Med"},{"issue":"9","key":"1535_CR22","doi-asserted-by":"publisher","first-page":"e005282","DOI":"10.1136\/jitc-2022-005282","volume":"10","author":"L Nadal","year":"2022","unstructured":"Nadal L, Peissert F, Elsayed A, Weiss T, Look T, Weller M, et al. Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody. J Immunother Cancer. 2022;10(9):e005282. https:\/\/doi.org\/10.1136\/jitc-2022-005282. PubMed PMID: 36104101; PubMed Central PMCID: PMCPMC9476130.","journal-title":"J Immunother Cancer."},{"issue":"10","key":"1535_CR23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol. 2018;36(10):440\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.005.","journal-title":"Urol Oncol"},{"issue":"1","key":"1535_CR24","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.1038\/s41467-025-62260-5","volume":"16","author":"X Qian","year":"2025","unstructured":"Qian X, Ning W, Yang J, Dunmall LC, Pandha HS, Shang G, et al. The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials. Nat Commun. 2025;16(1):6934. https:\/\/doi.org\/10.1038\/s41467-025-62260-5.","journal-title":"Nat Commun"},{"issue":"4","key":"1535_CR25","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/1078-0432.Ccr-06-1989","volume":"13","author":"BI Rini","year":"2007","unstructured":"Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007;13(4):1098\u2013106. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-1989. PubMed PMID: 17317817.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1535_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11523-025-01147-3","volume":"20","author":"M Schmidinger","year":"2025","unstructured":"Schmidinger M, Rane PP, Yan K, Druyts E, Burgents J, Sundaram M, et al. Efficacy of first-line treatments for advanced renal cell carcinoma: a Bayesian network meta-analysis of objective response, progression-free survival, and overall survival. Target Oncol. 2025;20(3):375\u201387. https:\/\/doi.org\/10.1007\/s11523-025-01147-3.","journal-title":"Target Oncol"},{"issue":"4","key":"1535_CR27","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.4049\/jimmunol.0903210","volume":"184","author":"EW Sorensen","year":"2010","unstructured":"Sorensen EW, Gerber SA, Frelinger JG, Lord EM. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol. 2010;184(4):1858\u201366. https:\/\/doi.org\/10.4049\/jimmunol.0903210. PubMed PMID: 20061409; PubMed Central PMCID: PMCPMC3070472. Epub 20100108.","journal-title":"J Immunol."},{"issue":"5","key":"1535_CR28","doi-asserted-by":"publisher","first-page":"e005813","DOI":"10.1136\/jitc-2022-005813","volume":"11","author":"J Strauss","year":"2023","unstructured":"Strauss J, Deville JL, Sznol M, Ravaud A, Maruzzo M, Pachynski RK, et al. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. J Immunother Cancer. 2023;11(5):e005813. https:\/\/doi.org\/10.1136\/jitc-2022-005813. PubMed PMID: 37236636; PubMed Central PMCID: PMCPMC10230972.","journal-title":"J Immunother Cancer."},{"issue":"7","key":"1535_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41581-023-00700-5","volume":"19","author":"MM Wolf","year":"2023","unstructured":"Wolf MM, Rathmell WK, de Cubas AA. Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. Nat Rev Nephrol. 2023;19(7):440\u201350. https:\/\/doi.org\/10.1038\/s41581-023-00700-5. PubMed PMID: 36973495; PubMed Central PMCID: PMCPMC10801831. Epub 20230327.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"1535_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1535_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12672-024-01011-2","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Sun X, Tong Y. Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity. Discov Oncol. 2024;15(1):170. https:\/\/doi.org\/10.1007\/s12672-024-01011-2.","journal-title":"Discov Oncol"},{"key":"1535_CR32","doi-asserted-by":"publisher","first-page":"116783","DOI":"10.1016\/j.biopha.2024.116783","volume":"176","author":"M Yang","year":"2024","unstructured":"Yang M, Mu Y, Yu X, Gao D, Zhang W, Li Y, et al. Survival strategies: how tumor hypoxia microenvironment orchestrates angiogenesis. Biomed Pharmacother. 2024;176:116783. https:\/\/doi.org\/10.1016\/j.biopha.2024.116783.","journal-title":"Biomed Pharmacother"},{"key":"1535_CR33","doi-asserted-by":"publisher","first-page":"175883592513853","DOI":"10.1177\/17588359251385392","volume":"17","author":"H Ying","year":"2025","unstructured":"Ying H, Tong F, Zhou Y, Zhou B, Qiao K, Chen L, et al. A cost-effectiveness comparison between immunotherapy combination regimens and sunitinib for advanced renal cell carcinoma in the USA and China. Ther Adv Med Oncol. 2025;17:17588359251385392. https:\/\/doi.org\/10.1177\/17588359251385392.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"1535_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/sj.mt.6300023","volume":"15","author":"JY Yoo","year":"2007","unstructured":"Yoo JY, Kim JH, Kwon YG, Kim EC, Kim NK, Choi HJ, et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther. 2007;15(2):295\u2013302. https:\/\/doi.org\/10.1038\/sj.mt.6300023. PubMed PMID: 17235307.","journal-title":"Mol Ther"},{"key":"1535_CR35","doi-asserted-by":"publisher","first-page":"216456","DOI":"10.1016\/j.canlet.2023.216456","volume":"579","author":"AR Yoon","year":"2023","unstructured":"Yoon AR, Hong J, Jung BK, Ahn HM, Zhang S, Yun CO. Oncolytic adenovirus as pancreatic cancer-targeted therapy: where do we go from here? Cancer Lett. 2023;579:216456. https:\/\/doi.org\/10.1016\/j.canlet.2023.216456.","journal-title":"Cancer Lett"},{"issue":"17","key":"1535_CR36","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1158\/0008-5472.CAN-18-3900","volume":"79","author":"AR Yoon","year":"2019","unstructured":"Yoon AR, Hong J, Li Y, Shin HC, Lee H, Kim HS, et al. Mesenchymal Stem Cell-Mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma. Cancer Res. 2019;79(17):4503\u201314. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3900.","journal-title":"Cancer Res"},{"issue":"10451","key":"1535_CR37","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet. 2024;404(10451):476\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(24)00917-6.","journal-title":"Lancet"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01535-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01535-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01535-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:22:48Z","timestamp":1790086968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01535-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1535"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01535-z","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is reported in accordance with the ARRIVE guidelines. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) (Hanyang University: HYU-2025-0025A HYU-2024-0278A and HYU-2025-0025A; Chung-Ang University approval number: A2021020) and conduct in accordance with relevant guidelines and regulations. No human participants were involved in this study. For institutional research integrity\/ethics inquiries, please contact: irb@hanyang.ac.kr (Institutional Review Board\/Research Ethics Office, Hanyang University).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"155"}}